Evidence map›Paper›PMID 39438453›Full record

ArticleBlood cancer journal2024

The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia.

Ronghua Zhang, Priyanka Khare, Priyanka Banerjee, Cristina Ivan, Sarah Schneider, Federica Barbaglio, Karen Clise-Dwyer, Vanessa Behrana Jensen, Erika Thompson, Marisela Mendoza and 15 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Epigenetics in B-CLL.International journal of genomics · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Ronghua Zhang *Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priyanka Khare *Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priyanka BanerjeeDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cristina IvanDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sarah SchneiderDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7027-7978
Federica BarbaglioDivision of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Karen Clise-DwyerDepartment of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vanessa Behrana JensenDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Erika ThompsonDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marisela MendozaDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicholas ChiorazziKarches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.ORCID 0000-0003-1023-6650
Shih-Shih ChenKarches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.ORCID 0000-0001-6258-1750
Xiao-Jie Joy YanKarches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paolo GhiaB cell neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0003-3750-7342
Federico Caligaris-CappioDivision of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Rima MendonsaNavan Technologies, Inc, San Carlos, CA, USA.
Sashi KasimsettyNavan Technologies, Inc, San Carlos, CA, USA.
Ryan SwobodaNavan Technologies, Inc, San Carlos, CA, USA.
Recep BayraktarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7357-270X
Varsha GandhiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3172-9166
George A CalinDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7427-0578
Michael J KeatingDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria Teresa Sabrina BertilaccioDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. MSBertilaccio@mdanderson.org.ORCID 0000-0002-2304-4618

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) Program Molecular Clinica Oncology-5 per mille number 9965CLL Global Research Foundation (CLL Global) N/ANCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The development and progression of chronic lymphocytic leukemia (CLL) depend on genetic abnormalities and on the immunosuppressive microenvironment. We have explored the possibility that genetic drivers might be responsible for the immune cell dysregulation that shapes the protumor microenvironment. We performed a transcriptome analysis of coding and non-coding RNAs (ncRNAs) during leukemia progression in the Rag2

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellMicroRNAsTumor MicroenvironmentAnimalsHumansMiceMultigene FamilyRNA, Long NoncodingTumor Suppressor ProteinsDLEU2 lncRNA, humanMicroRNAsMirn15a microRNA, mouseMIRN15 microRNA, humanMIRN16 microRNA, humanMirn16 microRNA, mouseRNA, Long NoncodingTumor Suppressor Proteins

Identifiers

PMID39438453
PMCPMC11496494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.